These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


164 related items for PubMed ID: 2908366

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
    Timar J, Knoll B, Knoll J.
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):255-66. PubMed ID: 3103558
    [Abstract] [Full Text] [Related]

  • 3. (-)Deprenyl (selegiline) is devoid of amphetamine-like behavioural effects in rats.
    Tímár J, Knoll B, Knoll J.
    Acta Physiol Hung; 1992 Dec; 79(2):131-7. PubMed ID: 1363925
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Behavioral effects of deprenyl in aged rats.
    Drago F, Continella G, Spadaro F, Cavaliere S, Scapagnini U.
    Funct Neurol; 1986 Dec; 1(2):165-74. PubMed ID: 3111946
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 2-Phenylethylamine in combination with l-deprenyl lowers the striatal level of dopamine and prolongs the duration of the stereotypy in mice.
    Kitanaka J, Kitanaka N, Tatsuta T, Takemura M.
    Pharmacol Biochem Behav; 2005 Nov; 82(3):488-94. PubMed ID: 16298423
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Further proof that (-)deprenyl fails to facilitate mesolimbic dopaminergic activity.
    Timár J, Gyarmati Z, Tekes K, Härsing GL, Knoll J.
    Pharmacol Biochem Behav; 1993 Nov; 46(3):709-14. PubMed ID: 8278449
    [Abstract] [Full Text] [Related]

  • 10. The effect of repeated administration of (-) deprenyl on the phenylethylamine-induced stereotypy in rats.
    Timár J, Knoll B.
    Arch Int Pharmacodyn Ther; 1986 Jan; 279(1):50-60. PubMed ID: 3083795
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine.
    Dalló J, Lekka N, Knoll J.
    Pol J Pharmacol Pharm; 1986 Jan; 38(3):251-5. PubMed ID: 3095802
    [Abstract] [Full Text] [Related]

  • 15. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP.
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT, Caprathe BW, Christoffersen CL, Corbin AE, Jaen JC, Ninteman FW, Pugsley TA, Serpa KA, Shih YH, Whetzel SZ.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.